OncoSec Revenue and Competitors
Estimated Revenue & Valuation
- OncoSec's estimated annual revenue is currently $4.8M per year.
- OncoSec's estimated revenue per employee is $155,000
Employee Data
- OncoSec has 31 Employees.
- OncoSec grew their employee count by -35% last year.
OncoSec Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is OncoSec?
OncoSec is a San Diego-based biotechnology company pioneering new technologies to stimulate the body's immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. Our technology, ImmunoPulse™, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. Clinical trials of ImmunoPulse™ IL-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. Our lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. To date, study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. We are witnessing the emergence of a new vision in the immunotherapy landscape – one that can capitalize on the ability of local therapy to drive a systemic anti-tumor immune response and overcome some of the limitations of traditional treatments. At OncoSec, we are advancing a new generation of cancer therapies that we hope will result in clinically meaningful benefits to patients who have limited or no available treatment options.
keywords:N/AN/A
Total Funding
31
Number of Employees
$4.8M
Revenue (est)
-35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OncoSec's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Clinical Trial Manager | Reveal Email/Phone |
2 | VP Clinical Development | Reveal Email/Phone |
3 | Quality Assurance Manager | Reveal Email/Phone |
4 | Director | Reveal Email/Phone |
5 | Senior Research Associate II | Reveal Email/Phone |
6 | CEO & Director | Reveal Email/Phone |
7 | CFO | Reveal Email/Phone |
8 | VP, Finance | Reveal Email/Phone |
9 | Sr. CRA | Reveal Email/Phone |
OncoSec News
OncoSec Medical logo Several brokerages have updated their recommendations and price targets on shares of OncoSec Medical (NASDAQ: ONCS) in...
Zacks Investment Research downgraded OncoSec Medical from a hold rating to a sell rating in a research report on Tuesday, April 12th. BTIG...
OncoSec Medical posted earnings of ($0.25) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 56%.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.6M | 31 | N/A | N/A |
#2 | $3.6M | 31 | N/A | N/A |
#3 | $3.6M | 31 | N/A | N/A |
#4 | $4.8M | 31 | 11% | N/A |
#5 | $2.4M | 31 | -6% | $37M |
OncoSec Executives
Name | Title |
---|---|
Robert Arch | President & CEO |
Punit Dhillon | Co-founder, Director, President & CEO |
Sharron Gargosky | Chief Clinical and Regulatory Officer |
Marge R. | Executive Assistant to the COO |
Brian Leuthner | Interim Chief Executive Officer |
Daniel O’Connor | CEO & Director |
Daniel O'Connor | CEO and Director |
George Chi | CFO |
Robert Arch | President & CEO |
Kim Jaffe | Associate Vice President of Business Development & Operations |
David Canton | Vice President, R&D |
Sandra Aung | Senior Vice President |
Bridget O'Keeffe | Vice President Clinical Development |
Punit Dhillon | Co-founder, Director, President & CEO |
Jeff Silverman | Vice President, Product Engineering |
Robert DelAversano | Vice President, Finance |
Bridget Okeeffe | Vice President, Clinical Development |
ROB SCHINAGL | Vice President, Program & Alliance Management |
David Canton | Vice President, R&d |